Myeloproliferative disorders

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 5, Issue 4, 2005, Pages 328-332

  Murray, Jim ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clonal evolution; Extramedullary; Haematocrit; Leuco erythroblastic; Leukaemogenesis; Non leukaemic; Transplantation

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; HYDROXYUREA; IMATINIB; PHOSPHORUS; THALIDOMIDE;

ANEMIA; BLEEDING; CLINICAL FEATURE; FIBROSIS; HEMATOCRIT; HUMAN; HYPERTENSION; LEUKEMIA; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NORMOCYTIC ANEMIA; OBESITY; PHLEBOTOMY; POLYCYTHEMIA VERA; PROGNOSIS; REVIEW; RISK FACTOR; SMOKING; THROMBOCYTHEMIA;

EID: 23844556856     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.5-4-328     Document Type: Review

References (14)

1. Pathology and genetics: tumours of haematopoietic and lymphoid tissues. In: Jaffe ES, Harris NL, Stein A, Vardiman JW (eds). World Health Organization classification of tumours. Lyon: IARC Press, 2001: 32-44.
2. Hoffbrand AV, Pettit JE, Moss PAH (eds). Essential haematology, 4th edn. Oxford: Blackwell Science, 2003.
3. Chievitz E, Thiede T. Complications and causes of death in polycythaemia vera. Acta Med Scand 1962;172:513-23.
4. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978;ii:1219-22.
5. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JT. Treatment of polycythaemia vera, a summary of clinical trends conducted by the Polycythaemia Vera Sub-Group. Philadelphia: W B Saunders, 1995: 166-94.
6. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1332-6.
7. Landolfi RM, Marchioli R, Kutti J, Gisslinger H et al; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-24.
8. McMullin MF, Bareford D, Campbell P, Green AR et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005 (in press).
9. Pearson TC. Apparent polycythaemia. Review. Blood Rev 1991;5:205-13.
10. Schafer AI. Thrombocytosis. Review. N Engl J Med 2004;350:1211-9.
11. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-6.
12. Harrison CN, Campbell PJ, Buck G, Wheatley K et al. A randomised comparison of hydroxyurea and anagrelide in high-risk essential thrombocythemia: the Medical Research Countil PT-1 Trial. N Engl J Med (in press).
13. Tefferi A. Myelofibrosis with myeloid metaplasia. Review. N Engl J Med 2000;342: 1255-65.
14. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia; a single-institution experience with 223 patients. Blood 2000;95:2226-33.